- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03564821
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
A Phase 1 Study of IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
This research study is studying a drug as a possible treatment for IDH1-mutant myeloid neoplasms.
-The drug involved in this study is ivosidenib (AG-120)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved ivosidenib as a treatment for any disease.
Ivosidenib is an inhibitor of the protein IDH1. Ivosidenib is currently being studied as a treatment for myeloid cancers like acute myeloid leukemia or myelodysplastic syndromes with an IDH1 mutation. This study is examining whether or not ivosidenib is beneficial and well-tolerated as an agent to prevent the relapse of IDH1-mutated acute myeloid leukemia or other myeloid neoplasms after hematopoietic stem cell transplantation. IDH1 is an enzyme that, when mutated, can overproduce metabolites (substances that help with metabolism) and compounds that contribute to the growth of tumors and cancerous cells. Ivosidenib may help block the over production of these substances and possibly reduce the chances of relapse.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- Johns Hopkins Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
Boston, Massachusetts, United States, 02214
- Massachusetts General Hospital
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pathologically confirmed diagnosis of IDH1(R132)-mutant acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). IDH1 mutations could have been detected by any mutational technique at any prior point including at diagnosis or remission.
- Between the ages of 18 and 75 years
- Will undergo allogeneic hematopoietic stem cell transplantation (HSCT) for their malignancy. Conditioning may be either conventional myeloablative (MAC) or reduced intensity conditioning (RIC).
HSCT Donor will be one of the following:
- 5/6 or 6/6 (HLA-A, B, DR) matched related donor
- 7/8 or 8/8 (HLA-A, B, DR, C) matched unrelated donor. Matching in the unrelated setting must be at the allele level.
- Haploidentical related donor, defined as ≥ 3/6 (HLA-A, B, DR) matched --≥ 4/6 (HLA-A, B, DR) umbilical cord blood (UCB). Matching in the UCB setting is at the antigen level. Recipients may receive either one or two UCB units. In the case of 2 UCB units, both units must have been at least 4/6 matched with the recipient.
- ECOG performance status ≤ 2
Participants must have normal organ and marrow function as defined below:
- Absolute neutrophil count ≥ 1000/µL without growth factor support (e.g. GCSF) in the previous 7 days
- Platelet count ≥ 50,000/µL without transfusional support in the previous 7 days
- AST (SGOT), ALT (SGPT) and Alkaline phosphatase < 3x institutional upper limit of normal (ULN)
- Direct bilirubin < 2.0 mg/dL
- Calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula)
- LVEF must be equal to or greater than 40%, as measured by MUGA scan or echocardiogram
- Female patients of childbearing potential must have a negative pregnancy test
- The effects of ivosidenib on the developing human fetus are unknown. For this reason female participants of child-bearing potential and male participants must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during the entire study treatment period and through 90 days after the last dose of treatment
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Prior allogeneic hematopoietic stem cell transplants.
- Evidence of relapsed/recurrent/residual disease as assessed by bone marrow aspirate and biopsy performed within 42 days prior to study entry.
History of other malignancy(ies) unless
- the participant has been disease-free for at least 5 years and is deemed by the investigator to be at low risk of recurrence of that malignancy, or
- the only prior malignancy was cervical cancer in situ and/or basal cell or squamous cell carcinoma of the skin
- Known diagnosis of active hepatitis B or hepatitis C
- Current or history of congestive heart failure New York Heart Association (NHYA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (LVEF < 40%, as measured by MUGA scan or echocardiogram)
- Current or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndrome
- QTc interval (i.e., Friderica's correction [QTcF]) ≥ 450 ms or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) at screening
- Systemic infection requiring IV antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection
- Uncontrolled intercurrent illness that would limit compliance with study requirements.
- HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with study drug. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ivosidenib (500mg/day)
-Ivosidenib will be administered orally every day
|
Ivosidenib is an inhibitor of the protein IDH1
|
Experimental: Ivosidenib (250mg/day)
-Ivosidenib will be administered orally every day
|
Ivosidenib is an inhibitor of the protein IDH1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose
Time Frame: 28 Days
|
Participants will be enrolled in standard 3 + 3 dose escalation cohorts in order to determine the maximum tolerated dose (MTD).
The first 3 participants will be started on 500mg of Ivosidenib, administered daily for 28 consecutive days (1 cycle).
If the 500mg/day dose level is tolerated, an additional 10 participants will be treated at this dose level.
If the 500mg/day dose is not tolerated, the dose will be decreased to 250mg/day.
If 250mg daily is tolerated, then an additional 10 participants will be treated at 250mg daily.
The only doses studied will be 500mg daily and 250mg daily (the latter, if necessary).
If 250mg daily dosing is not tolerated, then the study will end without expansion.
Dose limiting toxicities are assessed and graded using Common Terminology Criteria for Adverse Events (CTCAE 4).
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ivosidenib-related Adverse Events, categorized by grade
Time Frame: From the start of treatment until 30 days after the end of treatment, up to 13 months total
|
Adverse events will be assessed and graded using Common Terminology Criteria for Adverse Events (CTCAE 4).
|
From the start of treatment until 30 days after the end of treatment, up to 13 months total
|
Cumulative incidence of acute GVHD
Time Frame: From the start of treatment with Ivosidenib until the onset of Acute GVHD, up to 100 days
|
Cumulative incidence of acute graft versus host disease (GVHD), measured from start of treatment with Ivosidenib.
|
From the start of treatment with Ivosidenib until the onset of Acute GVHD, up to 100 days
|
Cumulative incidence of chronic GVHD
Time Frame: From the start of treatment with Ivosidenib until the onset of chronic GVHD, up to 24 months
|
The cumulative incidence of chronic GVHD, measured from start of treatment with Ivosidenib.
Chronic GVHD will be assessed using the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease.
|
From the start of treatment with Ivosidenib until the onset of chronic GVHD, up to 24 months
|
Plasma and marrow 2-hydroxyglutarate levels
Time Frame: Screening, cycle 1 days 8 and 15 (cycles are 28 days), before the start of cycles 2 and 3, and at the time of relapse; up 24 months total time
|
Screening, cycle 1 days 8 and 15 (cycles are 28 days), before the start of cycles 2 and 3, and at the time of relapse; up 24 months total time
|
|
IDH clonal evolution and mutational burden
Time Frame: Screening, cycle 1 days 8 and 15 (cycles are 28 days), before the start of cycles 2 and 3, and at the time of relapse; up 24 months total time
|
Isocitrate dehydrogenase (IDH) clonal evolution and mutational burden in patients with IDH1-mutant myeloid neoplasms who receive Ivosidenib after hematopoietic stem cell transplantation.
Next-generation sequencing will be used to assess mutational burden (i.e. the fraction of AML cells harboring IDH mutations, corrected for copy number) at various time points.
SNaPshot genotyping analysis platform will be used to perform these analyses.
|
Screening, cycle 1 days 8 and 15 (cycles are 28 days), before the start of cycles 2 and 3, and at the time of relapse; up 24 months total time
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amir T Fathi, MD, Massachusetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IDH1 Mutation Myeloid Neoplasms
-
Istituto Clinico HumanitasCelgeneUnknownAcute Myeloid Leukemia | IDH2 Gene Mutation | IDH1 Gene MutationItaly
-
AnHeart Therapeutics Inc.RecruitingIDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid TumorCholangiocarcinoma With IDH1 Mutation | Solid Tumors With IDH1 MutationChina
-
University of ChicagoRecruitingMyeloproliferative Neoplasm | Blood Cancer | IDH2 Gene Mutation | IDH1 Mutation | IDH MutationUnited States
-
Rigel PharmaceuticalsNationwide Children's HospitalNot yet recruitingAstrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditionsUnited States, Australia, United Kingdom, Canada, Germany, Netherlands
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Jason J. Luke, MDBristol-Myers Squibb; Agios Pharmaceuticals, Inc.CompletedGlioma | Advanced Solid Tumor | IDH1 MutationUnited States
-
Ruijin HospitalRecruitingP53 Mutation | Myeloid Malignancy | MDS | AmlChina
-
Li JunminUnknownAcute Myeloid Leukemia | P53 MutationChina
-
The First Affiliated Hospital of Soochow UniversityUnknown
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingAcute Myeloid Leukemia With FLT3/ITD MutationItaly
Clinical Trials on Ivosidenib
-
Servier Affaires MédicalesRecruitingCholangiocarcinomaFrance, Netherlands, Spain, Belgium, Sweden, Italy, Australia, Austria, Germany, United Kingdom
-
Servier Bio-Innovation LLCInstitut de Recherches Internationales ServierNot yet recruitingLocally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
-
Agios Pharmaceuticals, Inc.Approved for marketingAcute Myeloid Leukemia | Relapsed Pediatric AML | Relapsed Adult AML
-
CStone PharmaceuticalsCompletedRelapsed or Refractory Acute Myeloid LeukemiaChina
-
Agios Pharmaceuticals, Inc.Completed
-
Agios Pharmaceuticals, Inc.CompletedHepatic ImpairmentUnited States
-
Servier Affaires MédicalesRecruitingAcute Myeloid Leukemia (AML)Netherlands, Italy, Austria, France
-
Jason J. Luke, MDBristol-Myers Squibb; Agios Pharmaceuticals, Inc.CompletedGlioma | Advanced Solid Tumor | IDH1 MutationUnited States
-
iOMEDICO AGRecruitingAcute Myeloid Leukemia (AML)Germany
-
Memorial Sloan Kettering Cancer CenterAstellas Pharma US, Inc.RecruitingAcute Myeloid Leukemia (AML)United States